Topic: The Associated Press

When a drug's risks exceed its benefits, the federal Food and Drug Administration may ask or order a company to withdraw it from the market, or a company may do so on its own. Here are some drugs withdrawn in recent years.Mylotarg ...

Correction: Orexigen FDA story

Correction: Orexigen FDA StoryIn a story March 31 about Orexigen Therapeutics, The Associated Press erroneously reported the name of a competitor. The company is Arena Pharmaceuticals Inc., not Arena Therepeutics. Copyright 2010 AP News
EDITOR'S NOTE — An occasional look at how influence is exercised in Washington. By ALAN FRAM Associated Press Writer WASHINGTON (AP) — Chalk one up for the pharmaceutical lobby. The U.S. drug industry fended off price curbs and other hefty restrictions in ...
Clarification: Amylin FDA information request storyIn a story March 15, The Associated Press reported that Bydureon is the proposed trade name of exenatide, a diabetes treatment being developed by Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. The story should ...
EDITOR'S NOTE — An occasional look at how behind-the-scenes influence is exercised in Washington. By ALAN FRAM Associated Press Writer WASHINGTON (AP) — With the nation's $46 billion biological drug market at stake, the war between makers of the pricey biotech medicines ...